NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will host a conference call and webcast on Tuesday, June 24th to discuss Squalamine interim Phase II data in wet age-related macular degeneration (“wet-AMD”).
Help employers find you! Check out all the jobs and post your resume.
